Nissan and Renault have made their mutual cross-shareholdings equal at 15%, ironing out a source of friction in their alliance.
The Renault Group will transfer shares equivalent to 28.4 percent of the 43.4 percent stake it owns in Nissan Motor Co. to a French trust, retaining just a 15 percent stake, just as Nissan holds 15 percent of Renault.
The disparity between the holdings created conflicts, especially after Nissan became far more profitable than Renault.
The agreement on the change needs board approvals from both companies.
The companies did not reveal share buyers from the French trust, or the time frame for the sale.
Until then the voting rights would be “neutralized” for most managerial decisions, but the economic rights, such as dividends, will go to Renault.
The companies called the equalization of the crossholdings “an important milestone.”
The agreement calls for Nissan to invest in Ampere, Renault’s electric vehicle and software company. The companies will also work together on marketing, vehicles and technology in Latin America, India and Europe.
The French government is Renault’s top shareholder.


U.S. Stock Futures Steady as Oil Tops $100 Ahead of Inflation Data
Norway Core Inflation Rises to 3% in August
Asian Stocks Slide as Oil Surge Fuels Rate Hike Fears
Oil Prices Surge as Middle East Shipping Attacks Threaten Supply
Asian Currencies Subdued as Yen Weakens Ahead of Fed, BOJ Decisions
BOJ Set to Raise Rates to 1.25% as Inflation Risks Build
Elon Musk’s Boring Company Raises $3 Billion at $23 Billion Valuation
Fitch Eyes Japan Budget for Fiscal Discipline
UK Economy Grows 0.4% in July, Beating Forecasts
Gold Prices Steady as Hot PPI Boosts Fed Rate Hike Bets
Oil Prices Hold Near Highs as U.S.-Iran Conflict Escalates
Zara Owner Inditex Sales Rise 9% in August
OpenAI Agents Used Websites for Unauthorized Communications
US Treasury Yields Near 5% as Oil Fuels Inflation Fears
Global Central Banks Brace for More Rate Hikes as Inflation Risks Rise
U.S. Accuses Chinese AI Firms of Extracting Model Capabilities
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 



